NATICK, Mass., Aug. 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that results from studies involving the Company's Women's Health products will be presented at the Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA). The presentations will feature Boston Scientific's pelvic floor reconstruction systems and mid-urethral sling systems. The meeting will be held August 23-27 in Toronto.
Schedule of Key Presentations (All times are local; all events take place in the Metro Toronto Convention Centre.)
Wednesday, August 25
Poster Presentation: Ultrasonographic Scan Evaluation of Synthetic Mesh.Vincent Letouzey, M.D., will present a poster titled "Ultrasonographic Scan Evaluation of Synthetic Mesh Used for Vaginal Cystocele Repair Comparing Four Arms Transobturator Techniques to Anterior Bilateral Sacrospinous Ligament and Arcus Tendinous Suspension," during Poster Session 6 (Urodynamics and Imaging) at 5:10 p.m. in Room 701. The study evaluates post-procedure mesh contraction and placement of the Ugytex™ Transobturator Mesh and Pinnacle® Mesh using ultrasonography.
Friday, August 27
Poster Presentation: Evaluation of Lightweight Meshes. Barry O'Reilly, M.D., will present a poster titled "Evaluation of Local Tolerance of Lightweight Meshes in an Animal Model," during Poster Session 29 (Prolapse Surgery) at 3:45 pm in Room 717. The study assesses the local tolerance of the Polyform® Mesh and VitaMesh® Implant Pelvic Floor Reconstruction (PFR) meshes to other commercially available polypropylene meshes in modulating wound healing response.
Accepted Abstracts (Available at the ICS/IUGA booth and websites.)
This abstract describes results of a study to assess device-related serious adverse events, patient tolerability and the outcomes of a cough stress test in patients treated with the Solyx Single Incision Sling System.
This abstract describes results of a study to assess the pull-out forces of the Solyx Single Incision Sling, the Obtryx® Transobturator Sling and the Advantage® Retropubic Sling.
This abstract describes results of a study to evaluate the force required to remove a mesh leg from the sacrospinous ligaments if a surgeon feels the initial placement was not adequate and that readjustment is needed. The pull-out forces of the Pinnacle® PFR Kit and the Elevate® PFR Kit were measured and evaluated.
Boston Scientific's pelvic floor reconstruction systems include the Pinnacle® Pelvic Floor Kit Devices and the Uphold™ Vaginal Support System. In addition, the Company offers a complete line of mid-urethral sling systems for the treatment of stress urinary incontinence, including the Obtryx® Transobturator Mid-Urethral Sling System, the Solyx® Single Incision Sling System and the Advantage® Retropubic Sling. To learn more about these products, please visit the Women's Health section of the Boston Scientific website or Boston Scientific Women's Health Pelvic Floor Institute at www.pelvic-floor-institute.com.
Ugytex is a trademark of Sofradim Production. VitaMesh is a registered trademark of Proxy Biomedical.
About ICSThe International Continence Society is a society for medical professionals concerned with furthering education, scientific research and clinical practice, and with removing the stigma of incontinence. For more information, please visit: www.icsoffice.org.
About IUGAThe International Urogynecological Association is a non-profit international organization dedicated to the advancement of urogynecological knowledge around the world through education and the promotion of basic and clinical research on disorders of the female pelvic floor. For more information, please visit: www.iuga.org.
About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things our product performance, regulatory approval of our products, clinical studies, competitive offerings, our growth strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by ourselves and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document. CONTACT:
Paul Donovan508-650-8541 (office)508-667-5165 (mobile)Media RelationsBoston Scientific CorporationLarry Neumann508-650-8696 (office)Investor RelationsBoston Scientific Corporation
|SOURCE Boston Scientific Corporation|
Copyright©2010 PR Newswire.
All rights reserved